Technology areas: Biotechnology & Pharmaceuticals • Transportation, E-Commerce & Mechanical Systems
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Nippon Suisan Kaisha Ltd. is managing 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These 2 pending office actions are split between 2 distinct examiners, ensuring that no single individual controls the entire portfolio. Furthermore, the applications are being reviewed in 2 distinct art units, suggesting a breadth of technical subject matter within the pharmaceutical domain.
ROBINSON, HOPE A is the busiest examiner for the company, currently handling 1 pending office action. This 1 pending office action represents half of the total workload currently facing the entity. Because the 2 distinct examiners are located in 2 distinct art units, the prosecution strategy must be tailored to the specific standards of each administrative group.
The presence of 2 pending office actions across 2 distinct art units indicates that the Biotechnology & Pharmaceuticals filings may involve different biological or chemical processes. ROBINSON, HOPE A oversees 1 of these matters, while the other is handled by a second distinct examiner. This structure requires the practitioner to monitor two separate tracks of communication for the 2 pending office actions.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ROBINSON, HOPE A | 1 | 67.7% | +43.0% |
| ALMATRAHI, SAHAR FARIS | 1 | 29.7% | +57.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17526464 | METHOD OF PRODUCING MICROBIAL OIL CONTAINING FATTY ACIDS OBTAINED FROM LABYRINTHULID GENETICALLY MODIFIED BY GENE DISRUPTING OR TRANSFORMATION | ROBINSON, HOPE A | 55d |
| 16992774 | CEPHALOPOD FEEDER, FEEDING METHOD, AND CEPHALOPOD | ALMATRAHI, SAHAR FARIS | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17526464 | METHOD OF PRODUCING MICROBIAL OIL CONTAINING FATTY ACIDS OBTAINED FROM LABYRINTHULID GENETICALLY MODIFIED BY GENE DISRUPTING OR TRANSFORMATION | ROBINSON, HOPE A | 55d |
| 16992774 | CEPHALOPOD FEEDER, FEEDING METHOD, AND CEPHALOPOD | ALMATRAHI, SAHAR FARIS | — |
| Art Unit | Apps |
|---|---|
| 1652 | 1 |
| 3643 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17526464 | METHOD OF PRODUCING MICROBIAL OIL CONTAINING FATTY ACIDS OBTAINED FROM LABYRINTHULID GENETICALLY MODIFIED BY GENE DISRUPTING OR TRANSFORMATION | ROBINSON, HOPE A | 1652 | §102§112 | Non-Final OA | 55d | Pending | Nov 15, 2021 |
| 16992774 | CEPHALOPOD FEEDER, FEEDING METHOD, AND CEPHALOPOD | ALMATRAHI, SAHAR FARIS | 3643 | §103§112 | Final Rejection | — | Pending | Aug 13, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialNippon Suisan Kaisha Ltd. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Hope A Robinson has the most, with 1 of Nippon Suisan Kaisha Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
